• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)分子结构的全面综述:对对抗COVID-19的天然产物的见解。

A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19.

作者信息

Saied Essa M, El-Maradny Yousra A, Osman Alaa A, Darwish Amira M G, Abo Nahas Hebatallah H, Niedbała Gniewko, Piekutowska Magdalena, Abdel-Rahman Mohamed A, Balbool Bassem A, Abdel-Azeem Ahmed M

机构信息

Chemistry Department, Faculty of Science, Suez Canal University, Ismailia 41522, Egypt.

Institute for Chemistry, Humboldt Universität zu Berlin, Brook-Taylor-Str. 2, 12489 Berlin, Germany.

出版信息

Pharmaceutics. 2021 Oct 21;13(11):1759. doi: 10.3390/pharmaceutics13111759.

DOI:10.3390/pharmaceutics13111759
PMID:34834174
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8624722/
Abstract

In 2019, the world suffered from the emergence of COVID-19 infection, one of the most difficult pandemics in recent history. Millions of confirmed deaths from this pandemic have been reported worldwide. This disaster was caused by SARS-CoV-2, which is the last discovered member of the family of . Various studies have shown that natural compounds have effective antiviral properties against coronaviruses by inhibiting multiple viral targets, including spike proteins and viral enzymes. This review presents the classification and a detailed explanation of the SARS-CoV-2 molecular characteristics and structure-function relationships. We present all currently available crystal structures of different SARS-CoV-2 proteins and emphasized on the crystal structure of different virus proteins and the binding modes of their ligands. This review also discusses the various therapeutic approaches for COVID-19 treatment and available vaccinations. In addition, we highlight and compare the existing data about natural compounds extracted from algae, fungi, plants, and scorpion venom that were used as antiviral agents against SARS-CoV-2 infection. Moreover, we discuss the repurposing of select approved therapeutic agents that have been used in the treatment of other viruses.

摘要

2019年,全球遭遇了新型冠状病毒肺炎(COVID-19)感染的爆发,这是近代历史上最严重的大流行病之一。全球已报告数百万例因该大流行病导致的确诊死亡病例。这场灾难是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的,它是该病毒家族中最后被发现的成员。各种研究表明,天然化合物通过抑制包括刺突蛋白和病毒酶在内的多个病毒靶点,对冠状病毒具有有效的抗病毒特性。本综述介绍了SARS-CoV-2的分子特征和结构-功能关系的分类及详细解释。我们展示了不同SARS-CoV-2蛋白目前所有可用的晶体结构,并着重介绍了不同病毒蛋白的晶体结构及其配体的结合模式。本综述还讨论了COVID-19治疗的各种方法和可用疫苗。此外,我们强调并比较了从藻类、真菌、植物和蝎毒中提取的用作抗SARS-CoV-2感染抗病毒剂的天然化合物的现有数据。此外,我们还讨论了已批准用于治疗其他病毒的精选治疗药物的重新利用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/02394e07d4c9/pharmaceutics-13-01759-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/10532f3d54ca/pharmaceutics-13-01759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/9f6cdf29c2a4/pharmaceutics-13-01759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/760e4551e6a6/pharmaceutics-13-01759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/a4491391043d/pharmaceutics-13-01759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/721755d307ec/pharmaceutics-13-01759-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/e904b2f684a6/pharmaceutics-13-01759-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/68adabf0bb2d/pharmaceutics-13-01759-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/02394e07d4c9/pharmaceutics-13-01759-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/10532f3d54ca/pharmaceutics-13-01759-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/9f6cdf29c2a4/pharmaceutics-13-01759-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/760e4551e6a6/pharmaceutics-13-01759-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/a4491391043d/pharmaceutics-13-01759-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/721755d307ec/pharmaceutics-13-01759-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/e904b2f684a6/pharmaceutics-13-01759-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/68adabf0bb2d/pharmaceutics-13-01759-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/760b/8624722/02394e07d4c9/pharmaceutics-13-01759-g008.jpg

相似文献

1
A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)分子结构的全面综述:对对抗COVID-19的天然产物的见解。
Pharmaceutics. 2021 Oct 21;13(11):1759. doi: 10.3390/pharmaceutics13111759.
2
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.SARS-CoV-2 及其他人类致病冠状病毒的抗病毒药物和可用药靶的现状。
Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26.
3
Current Strategies of Antiviral Drug Discovery for COVID-19.新型冠状病毒肺炎抗病毒药物研发的当前策略
Front Mol Biosci. 2021 May 13;8:671263. doi: 10.3389/fmolb.2021.671263. eCollection 2021.
4
Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)相关的2019冠状病毒病大流行的出现、传播及潜在治疗靶点
Cell Physiol Biochem. 2020 Aug 25;54(4):767-790. doi: 10.33594/000000254.
5
Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.SARS-CoV-2 感染管理中潜在治疗靶点和抗病毒药物开发的方法和进展。
Eur J Pharmacol. 2020 Oct 15;885:173450. doi: 10.1016/j.ejphar.2020.173450. Epub 2020 Jul 31.
6
The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.新冠病毒-19(Sars-Cov-2)的英国变体不应造成疫苗问题。
J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):1-4. doi: 10.23812/21-3-E.
7
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防:回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
8
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
9
Comprehensive Analysis of SARS-COV-2 Drug Targets and Pharmacological Aspects in Treating the COVID-19.全面分析 SARS-CoV-2 药物靶点及治疗 COVID-19 的药理学作用
Curr Mol Pharmacol. 2022;15(2):393-417. doi: 10.2174/1874467214666210811120635.
10
Current Therapeutics for COVID-19, What We Know about the Molecular Mechanism and Efficacy of Treatments for This Novel Virus.新型冠状病毒肺炎的治疗现状:对该新型病毒治疗方法的分子机制和疗效的了解。
Int J Mol Sci. 2022 Jul 12;23(14):7702. doi: 10.3390/ijms23147702.

引用本文的文献

1
Prebiotic properties and antioxidant effect of crude extracts and polysaccharides from Agaricus bisporus and Pleurotus ostreatus mushrooms.双孢蘑菇和平菇粗提物及多糖的益生元特性与抗氧化作用
Sci Rep. 2025 Aug 24;15(1):31113. doi: 10.1038/s41598-025-16152-9.
2
Biochemical evaluation of novel thiazolone derivatives as dual α-glucosidase/α-amylase inhibitors, anti-inflammatory agents.新型噻唑啉酮衍生物作为双功能α-葡萄糖苷酶/α-淀粉酶抑制剂及抗炎剂的生化评价
Future Med Chem. 2025 Jan;17(2):209-219. doi: 10.1080/17568919.2024.2447225. Epub 2024 Dec 29.
3
Unlocking the pharmacological potential of Brennnesselwurzel (Urtica dioica L.): an in-depth study on multifaceted biological activities.

本文引用的文献

1
Potential of amentoflavone with antiviral properties in COVID-19 treatment.具有抗病毒特性的穗花杉双黄酮在新冠病毒肺炎治疗中的潜力
Asian Biomed (Res Rev News). 2021 Aug 20;15(4):153-159. doi: 10.2478/abm-2021-0020. eCollection 2021 Aug.
2
The Impact of Colchicine on COVID-19 patients: A Clinical Trial Study.秋水仙碱对新冠肺炎患者的影响:一项临床试验研究。
Mediterr J Rheumatol. 2022 Jun 30;33(2):232-236. doi: 10.31138/mjr.33.2.232. eCollection 2022 Jun.
3
A comprehensive review on current COVID-19 detection methods: From lab care to point of care diagnosis.
解锁荨麻(Urtica dioica L.)的药理潜力:对其多方面生物活性的深入研究。
BMC Complement Med Ther. 2024 Dec 18;24(1):413. doi: 10.1186/s12906-024-04709-6.
4
Novel Insights into the Antimicrobial and Antibiofilm Activity of Pyrroloquinoline Quinone (PQQ); , , and Shotgun Proteomic Studies.吡咯并喹啉醌 (PQQ) 的抗菌和抗生物膜活性的新见解;,和 shotgun 蛋白质组学研究。
Biomolecules. 2024 Aug 16;14(8):1018. doi: 10.3390/biom14081018.
5
Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritis targeting mi-RNA128a, TLR4 signaling pathway, and adenosine-induced FADD-microvesicular shedding: and study.解读曲美他嗪在类风湿性关节炎中的治疗潜力:靶向mi-RNA128a、TLR4信号通路以及腺苷诱导的FADD微泡脱落的研究
Front Pharmacol. 2024 Jun 11;15:1406939. doi: 10.3389/fphar.2024.1406939. eCollection 2024.
6
Anti-Viral Activity of Bioactive Molecules of Silymarin against COVID-19 via In Silico Studies.水飞蓟素生物活性分子通过计算机模拟研究对新冠病毒的抗病毒活性
Pharmaceuticals (Basel). 2023 Oct 17;16(10):1479. doi: 10.3390/ph16101479.
7
Unveiling the antitumor potential of novel N-(substituted-phenyl)-8-methoxycoumarin-3-carboxamides as dual inhibitors of VEGFR2 kinase and cytochrome P450 for targeted treatment of hepatocellular carcinoma.揭示新型N-(取代苯基)-8-甲氧基香豆素-3-甲酰胺作为VEGFR2激酶和细胞色素P450双重抑制剂在靶向治疗肝细胞癌方面的抗肿瘤潜力。
Front Chem. 2023 Aug 4;11:1231030. doi: 10.3389/fchem.2023.1231030. eCollection 2023.
8
Development of canagliflozin nanocrystals sublingual tablets in the presence of sodium caprate permeability enhancer: formulation optimization, characterization, , , and study.卡格列净纳米晶舌下片在月桂酸钠渗透促进剂存在下的研制:制剂优化、特性研究、 和 研究。
Drug Deliv. 2023 Dec;30(1):2241665. doi: 10.1080/10717544.2023.2241665.
9
Insight into the phytochemical profile and antimicrobial activities of and : an and study.对[具体植物名称1]和[具体植物名称2]的植物化学特征及抗菌活性的洞察:一项[研究方法1]和[研究方法2]研究。
Front Plant Sci. 2023 Apr 20;14:1136961. doi: 10.3389/fpls.2023.1136961. eCollection 2023.
10
Causal associations of tea intake with COVID-19 infection and severity.茶摄入量与新型冠状病毒肺炎感染及严重程度之间的因果关联。
Front Nutr. 2023 Jan 4;9:1005466. doi: 10.3389/fnut.2022.1005466. eCollection 2022.
关于当前新冠病毒检测方法的全面综述:从实验室检测到即时检测诊断
Sens Int. 2021;2:100119. doi: 10.1016/j.sintl.2021.100119. Epub 2021 Jul 24.
4
Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model. Griffithsin 和角叉菜胶联合使用对 SARS-CoV-1 和 2 在假病毒模型中具有抗病毒协同作用。
Mar Drugs. 2021 Jul 26;19(8):418. doi: 10.3390/md19080418.
5
Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19.关于免疫、药理学和对抗 COVID-19 的替代方法的最新进展。
Inflammopharmacology. 2021 Oct;29(5):1331-1346. doi: 10.1007/s10787-021-00850-7. Epub 2021 Jul 30.
6
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗(Ad5-nCoV)在成年人中的安全性、耐受性和免疫原性:一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
7
In silico investigation on the inhibitory effect of fungal secondary metabolites on RNA dependent RNA polymerase of SARS-CoV-II: A docking and molecular dynamic simulation study.计算机模拟研究真菌次生代谢产物对 SARS-CoV-2 依赖 RNA 的 RNA 聚合酶的抑制作用:对接和分子动力学模拟研究。
Comput Biol Med. 2021 Aug;135:104613. doi: 10.1016/j.compbiomed.2021.104613. Epub 2021 Jul 5.
8
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.通过对 6218 种药物和基于细胞的检测进行虚拟筛选,为 COVID-19 重新利用药物。
Proc Natl Acad Sci U S A. 2021 Jul 27;118(30). doi: 10.1073/pnas.2024302118.
9
Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting M and Ameliorates Pulmonary Inflammation.杨梅素通过靶向M蛋白抑制新型冠状病毒2型(SARS-CoV-2)病毒复制并减轻肺部炎症。
Front Pharmacol. 2021 Jun 17;12:669642. doi: 10.3389/fphar.2021.669642. eCollection 2021.
10
In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.计算机分析与鉴定新型冠状病毒 SARS-CoV-2 的 3-糜蛋白酶样主蛋白酶的抗病毒香豆素衍生物。
Mol Divers. 2022 Apr;26(2):1053-1076. doi: 10.1007/s11030-021-10230-6. Epub 2021 Jul 2.